Cullinan Oncology Analyst Ratings
Cullinan Oncology Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/11/2023 | 218.95% | HC Wainwright & Co. | $49 → $34 | Reiterates | Buy → Buy |
| 08/09/2023 | 359.66% | HC Wainwright & Co. | → $49 | Reiterates | → Buy |
| 07/07/2023 | 359.66% | HC Wainwright & Co. | → $49 | Reiterates | Buy → Buy |
| 06/15/2023 | — | TD Cowen | Initiates Coverage On | → Outperform | |
| 06/05/2023 | 359.66% | HC Wainwright & Co. | → $49 | Reiterates | Buy → Buy |
| 05/26/2023 | 359.66% | HC Wainwright & Co. | → $49 | Reiterates | Buy → Buy |
| 05/12/2023 | 359.66% | HC Wainwright & Co. | $50 → $49 | Maintains | Buy |
| 03/27/2023 | 369.04% | HC Wainwright & Co. | → $50 | Reiterates | → Buy |
| 03/10/2023 | 369.04% | HC Wainwright & Co. | → $50 | Reiterates | → Buy |
| 02/15/2023 | 369.04% | HC Wainwright & Co. | → $50 | Reiterates | → Buy |
| 02/03/2023 | 78.24% | Morgan Stanley | $27 → $19 | Maintains | Overweight |
| 11/21/2022 | 87.62% | BTIG | → $20 | Initiates Coverage On | → Buy |
| 05/13/2022 | 134.52% | SVB Leerink | $36 → $25 | Maintains | Outperform |
| 03/18/2022 | 397.19% | HC Wainwright & Co. | $55 → $53 | Maintains | Buy |
| 06/07/2021 | 303.38% | Morgan Stanley | $40 → $43 | Maintains | Overweight |
| 06/04/2021 | 415.95% | HC Wainwright & Co. | $48 → $55 | Maintains | Buy |
| 06/04/2021 | 406.57% | SVB Leerink | $48 → $54 | Maintains | Outperform |
| 04/27/2021 | — | Morgan Stanley | Upgrades | Equal-Weight → Overweight | |
| 04/19/2021 | 275.23% | Morgan Stanley | $38 → $40 | Maintains | Equal-Weight |
| 03/30/2021 | 350.28% | HC Wainwright & Co. | $47 → $48 | Maintains | Buy |
| 02/02/2021 | 415.95% | Evercore ISI Group | → $55 | Initiates Coverage On | → Outperform |
| 02/02/2021 | 387.8% | SVB Leerink | → $52 | Initiates Coverage On | → Outperform |
| 02/02/2021 | — | Morgan Stanley | Initiates Coverage On | → Equal-Weight | |
| 02/01/2021 | 340.9% | HC Wainwright & Co. | → $47 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目标价格变化 | 评级变化 | 上一次/当前评级 |
|---|---|---|---|---|---|
| 2023年08月11日 | 218.95% | HC Wainwright公司 | $49→$34 | 重申 | 购买→购买 |
| 08/09/2023 | 359.66% | HC Wainwright公司 | →$49 | 重申 | →购买 |
| 07/07/2023 | 359.66% | HC Wainwright公司 | →$49 | 重申 | 购买→购买 |
| 2023/06/15 | - | TD Cowen | 开始承保 | →跑赢大盘 | |
| 06/05/2023 | 359.66% | HC Wainwright公司 | →$49 | 重申 | 购买→购买 |
| 2023年05月26日 | 359.66% | HC Wainwright公司 | →$49 | 重申 | 购买→购买 |
| 2023年05月12日 | 359.66% | HC Wainwright公司 | $50→$49 | 维护 | 买 |
| 03/27/2023 | 369.04% | HC Wainwright公司 | →$50 | 重申 | →购买 |
| 03/10/2023 | 369.04% | HC Wainwright公司 | →$50 | 重申 | →购买 |
| 02/15/2023 | 369.04% | HC Wainwright公司 | →$50 | 重申 | →购买 |
| 02/03/2023 | 78.24% | 摩根士丹利 | $27→$19 | 维护 | 超重 |
| 2022年11月21日 | 87.62% | BTIG | →$20 | 开始承保 | →购买 |
| 2022年05月13日 | 134.52% | SVB Leerink | $36→$25 | 维护 | 跑赢大盘 |
| 03/18/2022 | 397.19% | HC Wainwright公司 | $55→$53 | 维护 | 买 |
| 06/07/2021 | 303.38% | 摩根士丹利 | $40→$43 | 维护 | 超重 |
| 06/04/2021 | 415.95% | HC Wainwright公司 | $48→$55 | 维护 | 买 |
| 06/04/2021 | 406.57% | SVB Leerink | $48→$54 | 维护 | 跑赢大盘 |
| 04/27/2021 | - | 摩根士丹利 | 升级 | 等重→超重 | |
| 04/19/2021 | 275.23% | 摩根士丹利 | $38→$40 | 维护 | 等重 |
| 03/30/2021 | 350.28% | HC Wainwright公司 | $47→$48 | 维护 | 买 |
| 02/02/2021 | 415.95% | Evercore ISI集团 | →$55 | 开始承保 | →跑赢大盘 |
| 02/02/2021 | 387.8% | SVB Leerink | →$52 | 开始承保 | →跑赢大盘 |
| 02/02/2021 | - | 摩根士丹利 | 开始承保 | →等重 | |
| 02/01/2021 | 340.9% | HC Wainwright公司 | →$47 | 开始承保 | →购买 |
What is the target price for Cullinan Oncology (CGEM)?
库利南肿瘤(CGEM)的目标价格是多少？
The latest price target for Cullinan Oncology (NASDAQ: CGEM) was reported by HC Wainwright & Co. on August 11, 2023. The analyst firm set a price target for $34.00 expecting CGEM to rise to within 12 months (a possible 218.95% upside). 12 analyst firms have reported ratings in the last year.
库利南肿瘤公司(纳斯达克代码：CGEM)的最新目标价是由HC Wainwright&Co.于2023年8月11日报道的。这家分析公司将目标价定为34美元，预计CGEM将在12个月内上涨(可能上涨218.95%)。去年有12家分析公司公布了评级。
What is the most recent analyst rating for Cullinan Oncology (CGEM)?
库利南肿瘤学(CGEM)的最新分析师评级是多少？
The latest analyst rating for Cullinan Oncology (NASDAQ: CGEM) was provided by HC Wainwright & Co., and Cullinan Oncology reiterated their buy rating.
对库利南肿瘤公司(纳斯达克代码：CGEM)的最新分析师评级是由HC Wainwright&Co.提供的，库利南肿瘤公司重申了他们的买入评级。
When is the next analyst rating going to be posted or updated for Cullinan Oncology (CGEM)?
库利南肿瘤学(CGEM)的下一次分析师评级将于何时发布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Cullinan Oncology, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Cullinan Oncology was filed on August 11, 2023 so you should expect the next rating to be made available sometime around August 11, 2024.
分析师在进行了广泛的研究后得出了股票评级，其中包括查阅公共财务报表，与库利南肿瘤公司的高管和客户交谈，以及听取收益电话会议。大多数分析师每三个月就会这样做一次，所以你每年应该会得到每家公司每家公司的4个评级。库利南肿瘤学的上一次评级是在2023年8月11日提交的，所以你应该预计下一次评级将在2024年8月11日左右提供。
Is the Analyst Rating Cullinan Oncology (CGEM) correct?
分析师对库利南肿瘤学(CGEM)的评级正确吗？
While ratings are subjective and will change, the latest Cullinan Oncology (CGEM) rating was a reiterated with a price target of $49.00 to $34.00. The current price Cullinan Oncology (CGEM) is trading at is $10.66, which is out of the analyst's predicted range.
虽然评级是主观的，并将发生变化，但最新的库利南肿瘤学(CGEM)评级被重申，目标价在49.00美元至34.00美元之间。库利南肿瘤公司(CGEM)目前的交易价格为10.66美元，超出了分析师的预测区间。